Ultimovacs has announced positive two-year overall survival (OS) data from a Phase I study (n=30) of UV1, a potential universal cancer vaccine, in combination with PD-1 immunotherapy (pembrolizumab, Merck) for the treatment of malignant melanoma. In this, the UV1/pembrolizumab combination demonstrated a 73% two-year OS rate, adding to data reported in March 2022 showing a complete response rate of 33% and an objective response rate (ORR) of 57%. Patients will be followed for further long-term survival data and management expect to report three-year OS data for the first cohort (n=20) in Q422. We continue to see the UV1/pembrolizumab combination in malignant melanoma as a potentially significant opportunity for the company. We value Ultimovacs at NOK6.90bn, or NOK202/share.Den vollständigen Artikel lesen ...